Features
As the pharmaceutical landscape continues to evolve, this issue highlights use of AI and GAMP® frameworks for different areas of the industry including quality and data management.
Categorization offers a useful starting point for assessing the risk of failure for individual software components, but it is not a validation checklist. Organizations must apply critical thinking to combine categorization with risk assessment and supplier assessments to appropriately scale life cycle activities and manage risk.
This article presents a model for promoting data quality of real-world data and evidence (RWD/RWE) and GxP processes with references to ISO 8000 for data quality management, making it a common language between regulated and nonregulated organizations.
Data integrity drives quality and compliance. Content addressable storage (CAS) stores and retrieves files by content type—not file location—using cryptographic fingerprints. The result: a mathematically provable version control, without broken links and far fewer audit headaches.
A single global digital chemistry, manufacturing, and controls (CMC) dossier is rapidly transitioning from a bold vision to a practical reality. However, realizing the full potential of these innovations requires significant coordination to harmonize and align across initiatives.
To accelerate the adoption of innovation in the global administration of the pharmaceutical industry, regulatory authorities and industry trade organizations must expand their scope and pursue a collaborative approach to recognition and reliance to streamline processes, enhance product quality, and improve patient access to medicines.
Thanabalan “Thana” Subramanian is Head of the Digital Quality team in the quality, regulatory, digital consultancy firm Product Life Group. He is responsible for a team of 20 consultants and supports the Digital Quality Center of Excellence, covering IT compliance, computer software validation (CSV), data integrity, CSV auditing, and CSV training. Before joining Integrity, he worked for...
Frank Henrichmann is an expert in quality management, computerized system validation, and compliance, especially in clinical trials and pharmacovigilance. With over 25 years of experience in quality functions within the pharmaceutical industry, he has gained deep expertise in implementing and validating computerized systems within GxP-regulated environments, having worked with organizations...
The 2025 ISPE D/A/CH workshop on “Pharma’s Journey to Digital Manufacturing and Supply” united pharma leaders, technology experts, and regulatory authorities for three days of intense exchange on the digital transformation of our industry.
Sustainability principles can be effectively integrated into commissioning and qualification (C&Q) projects to support environmental goals without compromising compliance, quality, or patient safety. By positioning C&Q as both a verification tool and an enabler of sustainable intent, this article outlines a practical path for the pharmaceutical sector to enhance operational efficiency,...
The pharmaceutical industry’s embrace of digital technologies and sustainability is no longer a competitive advantage, but an operational necessity. As Pharma 4.0™ matures, its integration will be vital for achieving net-zero objectives and achieving pharmaceutical excellence.
Crafting a sustainable packaging strategy for the pharmaceutical industry is complex and requires balancing environmental responsibility with regulatory compliance and operational costs. In this article, we explore the key drivers, challenges, and best practices for developing such a strategy.
The development of platform drug delivery devices for combination products offers a transformative approach to drug delivery by enabling the reuse of device data across multiple drug and device combinations.
Advancements in technology—such as process intensification, continuous manufacturing, and 3D printing—are enabling transportable and point-of-care (PoC) medicines manufacturing, especially with the rise of personalized medicine. Modular, small-scale production systems are particularly well-suited for cell and gene therapies and other advanced therapy medicinal products (ATMPs) designed for...
Simplified approaches that enable changes to analytical procedures over their lifecycle are needed to allow continual improvements and adaptations due to technological obsolescence and other challenges. This article reflects on the positive impact that the recent ICH Q14 guidance can have on facilitating these changes. Five examples are provided that are based on scenarios in which analytical...
The International Council for Harmonisation (ICH) Q2(R2) and Q14 guidelines, finalized in late 2023, outline strategies for analytical procedure development, validation, and lifecycle management. As global implementation progresses, ISPE’s PQLI® Analytical Method Strategy Team surveyed industry stakeholders in mid-2024 to assess readiness, identify opportunities, and highlight areas...
In April 2023, ISPE launched a survey to understand the sources of barriers to technological innovation within the pharmaceutical industry. This survey is part of an expansive and significant initiative by ISPE, Enabling Global Pharma Innovation: Delivering for Patients, which aims to promote consistent and harmonized interpretation and implementation of guidelines issued by the International...
Defining requirements for calibration and routine testing of weighing equipment in the laboratory and production remains a complex endeavor for pharmaceutical companies. Applying sound, risk-based metrological strategies across the entire pharmaceutical value chain will help manufacturers ensure compliance, consumer safety, and commercial success.
The United States Pharmacopeia (USP) Packaging and Distribution Expert Committee approved chapters 665 and 1665 in 2024. These chapters establish clear and general guidelines for the use of plastic materials in process equipment used within the pharmaceutical and biotechnology industries. Their publication has raised new questions regarding the role of polymeric materials in manufacturing...
The increasing digitalization of the pharmaceutical and medical device industry has created novel cybersecurity challenges, particularly with the rapid advancement of artificial intelligence (AI) technologies. This article examines the dual nature of AI as both a potential threat vector and a powerful defensive tool.
The move to digital transformation represents a true paradigm shift in manufacturing, enabling organizations to leverage advanced technologies such as the Industrial Internet of Things (IIoT), cloud computing, and artificial intelligence (AI) to ensure compliance and secure a competitive advantage. This article presents a working definition of digital transformation, the components involved in...
Currently, there is no single guidance document providing a comprehensive roadmap for executing digital validation. While elements from ISPE GAMP® Guides Series and the ISPE Baseline® Guide: Volume 8 – Pharma 4.0™, apply to digital validation, there is no consolidated resource addressing common questions. The authors of this Concept Paper therefore advocate for the development of a Good...
The evolution of pharmaceutical manufacturing has progressed through several stages—from manual drug compounding to fully automated lines with rigorous quality control. Today, a new era—Pharma 4.0™—is unfolding, offering both transformative opportunities and complex challenges driven by market needs, regulatory requirements, and rapid digital innovation.
Mike Martin, President and CEO of ISPE, recently connected with Nicholas Kapman, President and CEO of The FDA Group, a podcast that discusses current regulatory complexities facing the life science industry and explore innovative ways to overcome those challenges.
Pharmaceutical manufacturing faces mounting pressure to comply with stringent regulatory requirements while maintaining the highest standards of quality, speed, and efficiency. As digital transformation revolutionizes industries, artificial intelligence (AI) is emerging as a critical driver of change in reshaping how pharmaceutical companies operate. This article continues our exploration of...
Advanced therapy medicinal products (ATMPs) are redefining the boundaries of modern medicine. These cutting-edge treatments offer unprecedented opportunities to address complex diseases and deliver life-changing outcomes for patients. Yet, as this field rapidly evolves, so do the challenges—ranging from regulatory frameworks to manufacturing agility. To stay ahead, the industry must embrace...
To deliver meaningful value, a conference must truly reflect the current pulse of the pharmaceutical industry. This is easier said than done, as the sector is undergoing a profound and multifaceted transformation.
The journey of an ISPE Emerging Leader is one defined less by titles and more by growth, resilience, and the willingness to learn. Over the past several years, I’ve come to recognize a set of lessons that continue to guide my own path and the paths of many peers in the ISPE Emerging Leader community.
2025 was a remarkable year—one defined by resilience, growth, and meaningful celebration. Although the industry faced its share of challenges, our membership remained strong and steadfast.
The 2026 ISPE Facilities of the Future (FOF) Conference will be held 2–3 February in San Diego, California, United States, and virtually. Lindsey Daniel, the conference’s Executive Chair, offers advice and shares what attendees can expect at the upcoming conference.
As I assume the role of the 2025–2026 ISPE International Board of Directors Chair, I reflect on GAMP® not as a static set of practices, but as an evolving framework that has enabled our industry to embrace digitalization and innovation while also preserving the trust regulators and patients place in pharmaceutical manufacturing.
Pharmaceutical Engineering® is proud to announce that the 2024 Roger F. Sherwood Article of the Year is “3R Initiative Within Roche’s Global QC Network” (November/December 2024) by Sven M. Deutschmann, PhD.
ISPE names CSL Behring the 2025 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Project Aurora Plasma Base Fractionation Facility (Facility F). CSL Behring was honored with this prestigious award recognizing innovation and excellence in pharmaceutical facility projects, as the FOYA program celebrated its 20th anniversary.
The ISPE International Honor Awards provide the opportunity for all of us to recognize and celebrate the dedicated professionals volunteering countless hours to support ISPE in its mission.
ISPE elected a new 2025–2026 International Board of Directors, which is responsible for the governance and strategic direction of ISPE.
In each issue of Pharmaceutical Engineering®, we introduce a member of the ISPE staff who provides ISPE members with key information and services. Meet Gabriela Kantor, Technical Editor, Publications team.
Advanced therapy medicinal products (ATMPs) represent a revolutionary frontier in medicine, offering life-changing treatments for conditions previously deemed incurable. However, the intricate nature of these therapies, from their unique raw materials to complex manufacturing and logistics, presents significant challenges and inherent risks, including how to best develop validation methods and...
The newly published ISPE Good Practice Guide: Control Strategy Development for Continuous Manufacturing of Oral Solid Dosage Forms encourages broader adoption of continuous manufacturing (CM).
This article defines what constitutes a holistic control strategy in pharmaceutical development and manufacturing. It highlights the limitations of traditional, siloed approaches and demonstrates the added value of integrating these approaches across multiple dimensions. By identifying key gaps and proposing technological enablers, the article outlines a path toward a more comprehensive,...
In pharma, AI’s biggest challenge isn’t technical, it’s cultural.
2025 marks a significant milestone for the ISPE Argentina Affiliate with its 20th anniversary—commemorating two decades of commitment to excellence, collaboration, and integrity within the Latin American pharmaceutical community.
Laboratory automation in the pharmaceutical industry is rapidly evolving due to increasing regulatory demands and the need for efficiency, flexibility, and data integrity. However, fragmented systems, proprietary protocols, and inconsistent validation frameworks continue to limit progress.
The pharmaceutical industry is at a crossroads. Legacy systems, manual workflows, and paper-heavy processes are slowing down innovation.
Whether networking at events or collaborating through our Communities of Practice, the value of an ISPE membership is in the connections made between pharmaceutical industry professionals and Regulators to collaborate on solutions to common goals and challenges.
Are you a subject-matter expert in the global pharmaceutical industry? Are you brimming with knowledge about the latest technical developments or regulatory initiatives? Have you found an innovative solution to a real-world challenge?
Contribute your knowledge and experience to the always-evolving pharmaceutical industry!
Do you know someone whose profile or work should be featured in Pharmaceutical Engineering? Contact ISPE Publications Department.